- Home
- MFIN vs IMMP Comparison
MFIN vs IMMP Comparison
Compare MFIN & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- IMMP
- Stock Information
- Founded
- MFIN 1995
- IMMP 1987
- Country
- MFIN United States
- IMMP Australia
- Employees
- MFIN N/A
- IMMP N/A
- Industry
- MFIN Finance: Consumer Services
- IMMP Biotechnology: Pharmaceutical Preparations
- Sector
- MFIN Finance
- IMMP Health Care
- Exchange
- MFIN Nasdaq
- IMMP Nasdaq
- Market Cap
- MFIN 207.3M
- IMMP 211.1M
- IPO Year
- MFIN 1996
- IMMP N/A
- Fundamental
- Price
- MFIN $9.17
- IMMP $1.85
- Analyst Decision
- MFIN
- IMMP Buy
- Analyst Count
- MFIN 0
- IMMP 2
- Target Price
- MFIN N/A
- IMMP $8.50
- AVG Volume (30 Days)
- MFIN 43.3K
- IMMP 645.2K
- Earning Date
- MFIN 04-30-2025
- IMMP 05-16-2025
- Dividend Yield
- MFIN 4.80%
- IMMP N/A
- EPS Growth
- MFIN N/A
- IMMP N/A
- EPS
- MFIN 1.60
- IMMP N/A
- Revenue
- MFIN $316,751,000.00
- IMMP $3,019,249.00
- Revenue This Year
- MFIN N/A
- IMMP $11.25
- Revenue Next Year
- MFIN $6.21
- IMMP $10.22
- P/E Ratio
- MFIN $5.72
- IMMP N/A
- Revenue Growth
- MFIN 13.93
- IMMP 24.11
- 52 Week Low
- MFIN $6.48
- IMMP $1.32
- 52 Week High
- MFIN $10.50
- IMMP $3.34
- Technical
- Relative Strength Index (RSI)
- MFIN 60.44
- IMMP 53.09
- Support Level
- MFIN $9.00
- IMMP $1.44
- Resistance Level
- MFIN $9.34
- IMMP $2.71
- Average True Range (ATR)
- MFIN 0.28
- IMMP 0.18
- MACD
- MFIN 0.04
- IMMP 0.03
- Stochastic Oscillator
- MFIN 79.76
- IMMP 28.93
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.